RT Journal Article
T1 Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
A1 Paz-Ares, Luis
A1 Luft, Alexander
A1 Vicente, David
A1 Tafreshi, Ali
A1 Gümüş, Mahmut
A1 Mazières, Julien
A1 Hermes, Barbara
A1 Çay Şenler, Filiz
A1 Csőszi, Tibor
A1 Fülöp, Andrea
A1 Rodríguez-Cid, Jerónimo
A1 Wilson, Jonathan
A1 Sugawara, Shunichi
A1 Kato, Terufumi
A1 Lee, Ki Hyeong
A1 Cheng, Ying
A1 Novello, Silvia
A1 Halmos, Balazs
A1 Li, Xiaodong
A1 Lubiniecki, Gregory M
A1 Piperdi, Bilal
A1 Kowalski, Dariusz M
A1 KEYNOTE-407 Investigators, 
AB Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC. In this double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC to receive 200 mg of pembrolizumab or saline placebo for up to 35 cycles; all the patients also received carboplatin and either paclitaxel or nanoparticle albumin-bound [nab]-paclitaxel for the first 4 cycles. Primary end points were overall survival and progression-free survival. After a median follow-up of 7.8 months, the median overall survival was 15.9 months (95% confidence interval [CI], 13.2 to not reached) in the pembrolizumab-combination group and 11.3 months (95% CI, 9.5 to 14.8) in the placebo-combination group (hazard ratio for death, 0.64; 95% CI, 0.49 to 0.85; P In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by Merck Sharp & Dohme; KEYNOTE-407 ClinicalTrials.gov number, NCT02775435 .).
YR 2018
FD 2018-09-25
LK http://hdl.handle.net/10668/13017
UL http://hdl.handle.net/10668/13017
LA en
DS RISalud
RD Apr 4, 2025